Voleon Capital Management LP Purchases Shares of 55,962 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Voleon Capital Management LP acquired a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 55,962 shares of the company's stock, valued at approximately $443,000.

Several other large investors also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in Amneal Pharmaceuticals during the fourth quarter valued at $81,000. Straightline Group LLC purchased a new stake in Amneal Pharmaceuticals in the 4th quarter worth approximately $92,000. Cibc World Markets Corp bought a new stake in Amneal Pharmaceuticals during the 4th quarter worth approximately $118,000. Janney Montgomery Scott LLC purchased a new position in Amneal Pharmaceuticals during the fourth quarter valued at approximately $121,000. Finally, Fox Run Management L.L.C. boosted its position in shares of Amneal Pharmaceuticals by 69.0% in the fourth quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company's stock worth $162,000 after purchasing an additional 8,342 shares during the period. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX traded up $0.05 on Wednesday, reaching $7.23. The company's stock had a trading volume of 489,745 shares, compared to its average volume of 1,722,759. The company has a 50-day simple moving average of $7.98 and a 200 day simple moving average of $8.15. Amneal Pharmaceuticals, Inc. has a 52-week low of $6.29 and a 52-week high of $9.48. The company has a market cap of $2.24 billion, a P/E ratio of -10.62 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.05. The company had revenue of $695.42 million for the quarter, compared to analysts' expectations of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. On average, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on AMRX. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $9.00 to $12.00 in a report on Monday, February 24th. StockNews.com upgraded shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Monday. Finally, Barclays upped their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $11.50.

Insider Activity

In related news, Director Gautam Patel sold 80,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total transaction of $712,000.00. Following the completion of the sale, the director now directly owns 1,808,886 shares of the company's stock, valued at approximately $16,099,085.40. This trade represents a 4.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares of the company's stock, valued at $405,628,045.15. This represents a 9.33 % decrease in their position. The disclosure for this sale can be found here. Insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.